Aligos Therapeutics Inc (ALGS)

13.00 -0.70  -5.11% NASDAQ Dec 3, 16:00 13.00 0.00  0.00% After-Hours: 20:00 USD

Aligos Therapeutics Cash from Financing (TTM):

271.44M for Sept. 30, 2021
View 4,000+ financial data types
View Full Chart

Cash from Financing (TTM) Chart

Export Data
Save Image
Print Image

Historical Cash from Financing (TTM) Data

View and export this data going back to 2020. Start your Free Trial
Export Data Date Range:
Data for this Date Range  
Sept. 30, 2021 271.44M
June 30, 2021 192.54M
March 31, 2021 192.47M
Dec. 31, 2020 192.35M

There is no data for the selected date range.

An error occurred. Please try again by refreshing your browser or contact us with details of your problem.


Cash From Financing Definition

Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.

Read full definition.

Cash from Financing (TTM) Benchmarks

CEL-SCI Corp 54.29M
AIM ImmunoTech Inc 11.10M
NovaBay Pharmaceuticals Inc 1.999M

Cash from Financing (TTM) Range, Past 5 Years

Minimum 192.35M Dec 2020
Maximum 271.44M Sep 2021
Average 212.20M





Please note that this feature is only available as an add-on to YCharts subscriptions.

Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{}} No credit card required.

Already a subscriber? Sign in.